Besides, given the frequent expression on AML blasts and LSCs, yet limited expression on nonhematopoietic tissues and HSCs presented here and in previous reports [13–15, 28], CLL-1 may be one of the promising surface target molecules for AML. Here, CLEC12A is linked to acute myeloid leukemia.